Fibrinolytic Enhancement by Stanozolol: A Double Blind Trial
Fibrinolytic Enhancement by Stanozolol: A Double Blind Trial
复制标题
康力龙增强纤溶作用：双盲试验
DOI：
--
复制
发表时间：
1972
影响因子：
6.5
通讯作者：
G. Mcnicol
中科院分区：
文献类型：
--
作者：
J. Davidson;M. Lochhead;G. Mcdonald;G. Mcnicol
在一项双盲随机研究中，34名患有缺血性心脏病的男性患者接受了10 mg司坦唑醇/天、10 mg司坦唑醇+100 mg非那普利/天或安慰剂治疗12个月。每月进行一次纤溶和凝血试验。在整个研究期间，与基线值和安慰剂组相比，活性治疗组的血浆纤溶活性显著增强。两种活性治疗方案在增强纤溶方面均无显著差异，因此得出结论：在增加缺血性心脏病男性患者血浆纤溶活性方面，每日10 mg司坦唑醇与每日10 mg司坦唑醇加100 mg苯丙氨酸一样有效。
Thirty‐four men with ischaemic heart disease were given 10 mg stanozolol per day, 10 mg stanozolol plus 100 mg phenformin per day, or a placebo for 12 mth, in a double blind randomized study. A panel of fibrinolytic and coagulation tests was performed at monthly intervals. Throughout the study the groups on active treatment showed significant enhancement of plasma fibrinolytic activity compared with their base‐line values, and compared with the placebo group. No significant difference was found in the enhancement of fibrinolysis wliich was produced by either active treatment regimens, and it is concluded that 10 mg stanozolol daily‐is as effective as 10 mg stanozolol plus 100 mg phenformin daily in increasing plasma fibrinolytic activity in men with ischaemic heart disease.